Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Assets (2023 - 2025)

Historic Assets for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $39.8 million.

  • BioLineRx's Assets fell 2453.07% to $39.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.8 million, marking a year-over-year decrease of 2453.07%. This contributed to the annual value of $38.9 million for FY2024, which is 3913.81% down from last year.
  • Per BioLineRx's latest filing, its Assets stood at $39.8 million for Q3 2025, which was down 2453.07% from $43.3 million recorded in Q2 2025.
  • BioLineRx's 5-year Assets high stood at $68.6 million for Q1 2023, and its period low was $38.9 million during Q4 2024.
  • Over the past 3 years, BioLineRx's median Assets value was $52.7 million (recorded in 2024), while the average stood at $52.6 million.
  • Data for BioLineRx's Assets shows a peak YoY increase of 960.36% (in 2024) and a maximum YoY decrease of 3913.81% (in 2024) over the last 5 years.
  • BioLineRx's Assets (Quarter) stood at $63.9 million in 2023, then crashed by 39.14% to $38.9 million in 2024, then grew by 2.31% to $39.8 million in 2025.
  • Its Assets stands at $39.8 million for Q3 2025, versus $43.3 million for Q2 2025 and $43.5 million for Q1 2025.